Form4insider filings, from the source

SEC Form 4 · accession 0001140361-17-046572

Loxo Oncology, Inc. · LOXO

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Joshua H. Bilenker
Officer — President & CEO · Director
Period of report
Dec 14, 2017
Accepted (ET)
Dec 18, 2017 · 5:40 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001581720

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockDec 14, 2017M7,500$1.184A190,207D
Common StockF2,F3Dec 14, 2017S2,600$82.5465D187,607D
Common StockF2,F4Dec 14, 2017S2,900$83.4179D184,707D
Common StockF2,F5Dec 14, 2017S2,000$84.2935D182,707D
Common StockDec 15, 2017M7,500$1.184A190,207D
Common StockF2,F6Dec 15, 2017S700$76.9271D189,507D
Common StockF2,F7Dec 15, 2017S2,268$78.0645D187,239D
Common StockF2,F8Dec 15, 2017S3,023$78.9932D184,216D
Common StockF2,F9Dec 15, 2017S609$80.0822D183,607D
Common StockF2,F10Dec 15, 2017S600$80.8817D183,007D
Common StockDec 15, 2017S100$81.72D182,907D
Common StockDec 15, 2017S200$82.86D182,707D

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Employee Stock Option (right to buy)F11$1.184Dec 14, 2017M7,500D—Nov 14, 2023Common Stock7,50097,190D
Employee Stock Option (right to buy)F11$1.184Dec 15, 2017M7,500D—Nov 14, 2023Common Stock7,50089,690D

Explanation of responses